2021
DOI: 10.1086/712506
|View full text |Cite
|
Sign up to set email alerts
|

Killer Acquisitions

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

2
83
0
3

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 264 publications
(104 citation statements)
references
References 100 publications
2
83
0
3
Order By: Relevance
“…Of course, these are the cases that matter in practice, as enforcers would not be likely to assess a merger in a fragmented industry with many competing players. Similarly, Cunningham et al (2020) provide robust evidence of innovation concerns in the pharmaceutical industry. In their study of a large number of pharmaceutical acquisitions, incumbent firms often acquire innovative targets solely to discontinue the target's innovation projects and thus pre-empt future competition.…”
Section: Practice Of Mergers and Innovationmentioning
confidence: 87%
“…Of course, these are the cases that matter in practice, as enforcers would not be likely to assess a merger in a fragmented industry with many competing players. Similarly, Cunningham et al (2020) provide robust evidence of innovation concerns in the pharmaceutical industry. In their study of a large number of pharmaceutical acquisitions, incumbent firms often acquire innovative targets solely to discontinue the target's innovation projects and thus pre-empt future competition.…”
Section: Practice Of Mergers and Innovationmentioning
confidence: 87%
“…Our model's most apparent limitation concerns the baseline replicator dynamics equation, though, which implies that the emergent concentration is 'good concentration' (Covarrubias et al 2020) and fully justifiable by productivity differences. Empirically, it is questionable if concentration indeed only reflects productivity (Covarrubias et al 2020), with firms erecting artificial barriers to entry or acquiring competitors and discontinuing their innovative product lines in so-called 'killer acquisitions' (Cunningham et al 2021) leading to 'bad concentration'. Since it is at least conceivable that a high concentration of the good type is preferable to lower bad concentration, the inclusion of strategic anticompetitive behaviour might alter the policy conclusions of our model and tilt them more towards antitrust measures, which might like in our baseline model induce high ex-post concentration purely based on productivity differences.…”
Section: Discussionmentioning
confidence: 99%
“…This is well documented in other information-based sectors, such as pharma and microprocessors (Feldman et al 2020). Cunningham, Ma and Ederer (2021), for instance estimate (conservatively, they say) that between 5.3% and 7.4% of US acquisitions between 1989 and 2010 were "acquire to kill", and thus harmful for both innovation and competition.…”
Section: Start-ups and The Geography Of Big Tech Acquisitionsmentioning
confidence: 99%